🟢 Outlook Therapeutics is trading 6.11% up in pre-market after two sharply weaker sessions

Outlook Therapeutics is trading 6.11% up at $0.80 in pre-market, possibly reflecting a rebound after two sharply weaker sessions.

• It closed at $0.76 on August 14, 2026.
• Third-quarter revenue was $9,000 and missed estimates; management reiterated a late-2026 LYTENAVA U.S. launch and disclosed approximately $51.1 million in net offering proceeds.
• No new company-specific announcement for August 17, 2026 was identified; the Nasdaq was firmer pre-market.